# A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)

> **NCT05029895** · — · COMPLETED · sponsor: **AbbVie** · enrollment: 167 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05029895
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-29
- **Primary completion:** 2025-09-17
- **Final completion:** 2025-09-17
- **Target enrollment:** 167 (ACTUAL)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05029895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05029895, "A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05029895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*